Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation

Authors: Lars Erik Podleska, Thorsten Poeppel, Michael Herbrik, Lisa Dahlkamp, Florian Grabellus, Georg Taeger

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Exact drug dosing in isolated limb perfusion (ILP) and infusion (ILI) is essential. We developed and evaluated a model for calculating the volume of extremities and compared this model with body weight- and height-dependent parameters.

Methods

The extremity was modeled by a row of coupled truncated cones. The sizes of the truncated cone bases were derived from the circumference measurements of the extremity at predefined levels (5 cm). The resulting volumes were added. This extremity volume model was correlated to the computed tomography (CT) volume data of the extremity (total limb volume). The extremity volume was also correlated with the patient’s body weight, body mass index (BMI) and ideal body weight (IBW). The no-fat CT limb volume was correlated with the circumference-measured limb volume corrected by the ideal-body-weight to actual-body-weight ratio (IBW corrected-limb-volume).

Results

The correlation between the CT volume and the volume measured by the circumference was high and significant. There was no correlation between the limb volume and the bare body weight, BMI or IBW. The correlation between the no-fat CT volume and IBW-corrected limb volume was high and significant.

Conclusions

An appropriate drug dosing in ILP can be achieved by combining the limb volume with the simple circumference measurements and the IBW to body-weight ratio.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007, 25: 4707-4713. 10.1200/JCO.2007.11.2938.CrossRefPubMed Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007, 25: 4707-4713. 10.1200/JCO.2007.11.2938.CrossRefPubMed
2.
go back to reference Pai MP: Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012, 32: 856-868. 10.1002/j.1875-9114.2012.01108.x.CrossRefPubMed Pai MP: Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012, 32: 856-868. 10.1002/j.1875-9114.2012.01108.x.CrossRefPubMed
3.
go back to reference Grabellus F, Kraft C, Sheu-Grabellus SY, Bauer S, Podleska LE, Lauenstein TC, Pottgen C, Konik MJ, Schmid KW, Taeger G: Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. J Surg Oncol. 2011, 103: 371-379. 10.1002/jso.21724.CrossRefPubMed Grabellus F, Kraft C, Sheu-Grabellus SY, Bauer S, Podleska LE, Lauenstein TC, Pottgen C, Konik MJ, Schmid KW, Taeger G: Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. J Surg Oncol. 2011, 103: 371-379. 10.1002/jso.21724.CrossRefPubMed
4.
go back to reference Deroose JP, van Geel AN, Burger JW, Eggermont AM, Verhoef C: Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol. 2011, 105: 563-569.CrossRefPubMed Deroose JP, van Geel AN, Burger JW, Eggermont AM, Verhoef C: Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol. 2011, 105: 563-569.CrossRefPubMed
5.
go back to reference Deroose JP, Eggermont AM, van Geel AN, Burger JW, den Bakker MA, de Wilt JH, Verhoef C: Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011, 29: 4036-4044. 10.1200/JCO.2011.35.6618.CrossRefPubMed Deroose JP, Eggermont AM, van Geel AN, Burger JW, den Bakker MA, de Wilt JH, Verhoef C: Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011, 29: 4036-4044. 10.1200/JCO.2011.35.6618.CrossRefPubMed
6.
go back to reference Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S: Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008, 24: 193-203. 10.1080/02656730701868387.CrossRefPubMed Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S: Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008, 24: 193-203. 10.1080/02656730701868387.CrossRefPubMed
7.
go back to reference Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006, 106: 1776-1784. 10.1002/cncr.21802.CrossRefPubMed Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006, 106: 1776-1784. 10.1002/cncr.21802.CrossRefPubMed
8.
go back to reference Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996, 224: 756-764. 10.1097/00000658-199612000-00011. discussion 764–765PubMedCentralCrossRefPubMed Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996, 224: 756-764. 10.1097/00000658-199612000-00011. discussion 764–765PubMedCentralCrossRefPubMed
9.
go back to reference Deroose JP, Grunhagen DJ, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C: Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br J Surg. 2011, 98: 1573-1580. 10.1002/bjs.7621.CrossRefPubMed Deroose JP, Grunhagen DJ, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C: Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br J Surg. 2011, 98: 1573-1580. 10.1002/bjs.7621.CrossRefPubMed
10.
go back to reference Deroose JP, Eggermont AM, van Geel AN, Verhoef C: Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol. 2011, 23: 183-188. 10.1097/CCO.0b013e3283424dbc.CrossRefPubMed Deroose JP, Eggermont AM, van Geel AN, Verhoef C: Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol. 2011, 23: 183-188. 10.1097/CCO.0b013e3283424dbc.CrossRefPubMed
11.
go back to reference Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusion for melanoma patients–a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006, 32: 371-380. 10.1016/j.ejso.2006.01.015.CrossRefPubMed Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusion for melanoma patients–a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol. 2006, 32: 371-380. 10.1016/j.ejso.2006.01.015.CrossRefPubMed
12.
go back to reference Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C: 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol. 2012, 19: 627-635. 10.1245/s10434-011-2030-7.PubMedCentralCrossRefPubMed Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C: 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol. 2012, 19: 627-635. 10.1245/s10434-011-2030-7.PubMedCentralCrossRefPubMed
13.
go back to reference Duprat Neto JP, Oliveira F, Bertolli E, Molina AS, Nishinari K, Facure L, Fregnani JH: Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity. Clinics (Sao Paulo). 2012, 67: 237-241. 10.6061/clinics/2012(03)06.CrossRef Duprat Neto JP, Oliveira F, Bertolli E, Molina AS, Nishinari K, Facure L, Fregnani JH: Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity. Clinics (Sao Paulo). 2012, 67: 237-241. 10.6061/clinics/2012(03)06.CrossRef
14.
go back to reference Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS: Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009, 16: 2570-2578. 10.1245/s10434-009-0563-9.CrossRefPubMed Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS: Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009, 16: 2570-2578. 10.1245/s10434-009-0563-9.CrossRefPubMed
15.
go back to reference Grunhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM: TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol. 2005, 31: 1011-1019. 10.1016/j.ejso.2005.07.003.CrossRefPubMed Grunhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM: TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol. 2005, 31: 1011-1019. 10.1016/j.ejso.2005.07.003.CrossRefPubMed
16.
go back to reference Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982, 18: 905-910. 10.1016/0277-5379(82)90235-8.CrossRefPubMed Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982, 18: 905-910. 10.1016/0277-5379(82)90235-8.CrossRefPubMed
17.
go back to reference van Os J, Schraffordt Koops H, Oldhoff J: Dosimetry of cytostatics in hyperthermic regional isolated perfusion. Cancer. 1985, 55: 698-701. 10.1002/1097-0142(19850215)55:4<698::AID-CNCR2820550404>3.0.CO;2-2.CrossRefPubMed van Os J, Schraffordt Koops H, Oldhoff J: Dosimetry of cytostatics in hyperthermic regional isolated perfusion. Cancer. 1985, 55: 698-701. 10.1002/1097-0142(19850215)55:4<698::AID-CNCR2820550404>3.0.CO;2-2.CrossRefPubMed
18.
go back to reference Byrne DS, McKay AJ, Blackie R, MacKie RM: A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Eur J Cancer. 2082–2087, 1996: 32A- Byrne DS, McKay AJ, Blackie R, MacKie RM: A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Eur J Cancer. 2082–2087, 1996: 32A-
19.
go back to reference McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros W, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS: Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?. Ann Surg Oncol. 2009, 16: 953-961. 10.1245/s10434-008-0288-1.CrossRefPubMed McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros W, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS: Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?. Ann Surg Oncol. 2009, 16: 953-961. 10.1245/s10434-008-0288-1.CrossRefPubMed
20.
go back to reference Huismans AM, Kroon HM, Haydu LE, Kam PC, Thompson JF: Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?. Ann Surg Oncol. 2012, 19: 3050-3056. 10.1245/s10434-012-2316-4.CrossRefPubMed Huismans AM, Kroon HM, Haydu LE, Kam PC, Thompson JF: Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?. Ann Surg Oncol. 2012, 19: 3050-3056. 10.1245/s10434-012-2316-4.CrossRefPubMed
21.
go back to reference Kam PC, Thompson JF: Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Expert Opin Drug Metab Toxicol. 2010, 6: 1039-1045. 10.1517/17425255.2010.503703.CrossRefPubMed Kam PC, Thompson JF: Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Expert Opin Drug Metab Toxicol. 2010, 6: 1039-1045. 10.1517/17425255.2010.503703.CrossRefPubMed
22.
go back to reference Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M: Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med. 1979, 90: 185-187. 10.7326/0003-4819-90-2-185.CrossRefPubMed Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M: Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med. 1979, 90: 185-187. 10.7326/0003-4819-90-2-185.CrossRefPubMed
23.
go back to reference Luciani A, Rusko L, Baranes L, Pichon E, Loze B, Deux JF, Laurent A, Tran-Van-Nhieu J, Rahmouni A: Automated liver volumetry in orthotopic liver transplantation using multiphase acquisitions on MDCT. AJR Am J Roentgenol. 2012, 198: W568-W574. 10.2214/AJR.11.7468.CrossRefPubMed Luciani A, Rusko L, Baranes L, Pichon E, Loze B, Deux JF, Laurent A, Tran-Van-Nhieu J, Rahmouni A: Automated liver volumetry in orthotopic liver transplantation using multiphase acquisitions on MDCT. AJR Am J Roentgenol. 2012, 198: W568-W574. 10.2214/AJR.11.7468.CrossRefPubMed
24.
go back to reference Gao L, Heath DG, Kuszyk BS, Fishman EK: Automatic liver segmentation technique for three-dimensional visualization of CT data. Radiology. 1996, 201: 359-364.CrossRefPubMed Gao L, Heath DG, Kuszyk BS, Fishman EK: Automatic liver segmentation technique for three-dimensional visualization of CT data. Radiology. 1996, 201: 359-364.CrossRefPubMed
25.
go back to reference Frericks BB, Caldarone FC, Nashan B, Savellano DH, Stamm G, Kirchhoff TD, Shin HO, Schenk A, Selle D, Spindler W, Klempnauer J, Peitgen HO, Galanski M: 3D CT modeling of hepatic vessel architecture and volume calculation in living donated liver transplantation. Eur Radiol. 2004, 14: 326-333. 10.1007/s00330-003-2161-8.CrossRefPubMed Frericks BB, Caldarone FC, Nashan B, Savellano DH, Stamm G, Kirchhoff TD, Shin HO, Schenk A, Selle D, Spindler W, Klempnauer J, Peitgen HO, Galanski M: 3D CT modeling of hepatic vessel architecture and volume calculation in living donated liver transplantation. Eur Radiol. 2004, 14: 326-333. 10.1007/s00330-003-2161-8.CrossRefPubMed
26.
go back to reference Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996, 14: 2653-2665.PubMed Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996, 14: 2653-2665.PubMed
27.
go back to reference Grabellus F, Kraft C, Sheu SY, Ebeling P, Bauer S, Lendemans S, Schmid KW, Taeger G: Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol. 2009, 16: 676-686. 10.1245/s10434-008-0277-4.CrossRefPubMed Grabellus F, Kraft C, Sheu SY, Ebeling P, Bauer S, Lendemans S, Schmid KW, Taeger G: Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol. 2009, 16: 676-686. 10.1245/s10434-008-0277-4.CrossRefPubMed
29.
go back to reference Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS: Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008, 15: 2195-2205. 10.1245/s10434-008-9988-9.CrossRefPubMed Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS: Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008, 15: 2195-2205. 10.1245/s10434-008-9988-9.CrossRefPubMed
30.
go back to reference Kroon HM, Moncrieff M, Kam PC, Thompson JF: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009, 16: 1184-1192. 10.1245/s10434-009-0323-x.CrossRefPubMed Kroon HM, Moncrieff M, Kam PC, Thompson JF: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009, 16: 1184-1192. 10.1245/s10434-009-0323-x.CrossRefPubMed
Metadata
Title
Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation
Authors
Lars Erik Podleska
Thorsten Poeppel
Michael Herbrik
Lisa Dahlkamp
Florian Grabellus
Georg Taeger
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-81

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue